Prof. Dr. FATİH DEMİRKAN

Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis , cilt.61, ss.103373, 2022 (SCI-Expanded, Scopus)

33. Prospective registry of adult patients receiving therapeutic plasma exchange with a presumptive diagnosis of thrombotic microangiopathy (TMA): The Turkish hematology research and education group (ThREG)-TMA02 study.

Akpinar S., Tekgunduz E., Esen R., Yilmaz M., Karakus V., Vural F., et al.

Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis , cilt.61, ss.103365, 2022 (SCI-Expanded, Scopus)

34. Real-Life Experience Regarding Clinical Characteristics and Treatment Outcome in Non-Cutaneous Peripheral T-Cell Lymphomas: A Multicenter Study of the Turkish Hematology Research and Education Group (ThREG) Non-kutanöz Periferik T-hücreli Lenfomalarda Klinik Özellikler ve Tedavi Sonuçlarına ilişkin Gerçek Yaşam Deneyimi:Türk Hematoloji Araştırma ve Eğitim Grubunun Çok Merkezli Çalışması

Kayıkçı Ö., Mehtap Ö., Sarı İ., Demirkan F., Beyan C., Çetin G., et al.

Turkish Journal of Hematology , cilt.39, sa.3, ss.170-177, 2022 (SCI-Expanded, Scopus, TRDizin)

35. Assessment of Bone Marrow Biopsy and Cytogenetic Findings in Patients with Multiple Myeloma

Seyhanlı A., Yavuz B., Akşit Z., Yüce Z., Özkal S., Altungöz O., et al.

TURKISH JOURNAL OF HEMATOLOGY , cilt.39, sa.2, ss.109-116, 2022 (SCI-Expanded, Scopus, TRDizin)

36. Evaluation of using fresh frozen plasma for patients with cirrhosis at a tertiary healthcare center in Turkey: Strict transfusion policies are essential

Seyhanli A., ÖZKAN Y. C., BENGİ G., ALACACIOĞLU İ., ÖZSAN G. H., DEMİRKAN F.

TRANSFUSION AND APHERESIS SCIENCE , cilt.60, sa.6, 2021 (SCI-Expanded, Scopus)

37. Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study

Greil R., Tedeschi A., Moreno C., Anz B., Larratt L., Simkovic M., et al.

ANNALS OF HEMATOLOGY , cilt.100, sa.7, ss.1733-1742, 2021 (SCI-Expanded, Scopus)

38. Evaluation of Cardiac Repolarization in the Randomized Phase 2 Study of Intermediate- or High-Risk Smoldering Multiple Myeloma Patients Treated with Daratumumab Monotherapy

Chari A., Munder M., Weisel K., Jenner M., Bygrave C., Petrucci M. T., et al.

ADVANCES IN THERAPY , cilt.38, sa.2, ss.1328-1341, 2021 (SCI-Expanded, Scopus)

39. Which prognostic marker is responsible for the clinical heterogeneity in CLL with 13q deletion?

DURAK ARAS B., IŞIK S., ÜSKÜDAR TEKE H., Aslan A., Yavasoglu F., Gulbas Z., et al.

MOLECULAR CYTOGENETICS , cilt.14, sa.1, 2021 (SCI-Expanded, Scopus)

40. Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma

Fraser G. A. M., Chanan-Khan A., DEMİRKAN F., Santucci Silva R., Grosicki S., Janssens A., et al.

LEUKEMIA & LYMPHOMA , cilt.61, sa.13, ss.3188-3197, 2020 (SCI-Expanded, Scopus)

41. Real-World Data from the Turkish National Chronic Lymphocytic Leukemia Registry

DEMİRKAN F., Sevindik O. G.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , cilt.20, 2020 (SCI-Expanded, Scopus)

42. Neutropenia Analysis of Venetoclax Monotherapy in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Pooled Data from VENICE-I and -II Phase 3b Trials

Anderson M. A., Davids M. S., Kater A. P., Cochrane T., DEMİRKAN F., Herishanu Y., et al.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , cilt.20, 2020 (SCI-Expanded, Scopus)

43. A cross-trial comparison of single-agent ibrutinib versus chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma

Tedeschi A., Greil R., DEMİRKAN F., Robak T., Moreno C., Barr P. M., et al.

HAEMATOLOGICA , cilt.105, sa.4, 2020 (SCI-Expanded, Scopus)

44. Minimal residual disease response with venetoclax monotherapy in relapsed/refractory CLL patients: VENICE I, phase 3b exploratory analysis

Kater A., Panagiotis P., Aktan M., ARSLAN Ö., DEMİRKAN F., Enggaard L., et al.

LEUKEMIA & LYMPHOMA , cilt.61, ss.113-115, 2020 (SCI-Expanded, Scopus)

45. What are the factors affecting survival after autologous stem cell transplantation in patients with multiple myeloma?

Solmaz S., Acar C., Seyhanli A., Sevindik O. G., Piskin O., ÖZCAN M. A., et al.

INDIAN JOURNAL OF TRANSPLANTATION , cilt.14, sa.1, ss.57-62, 2020 (ESCI, Scopus)

46. Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS Trial

Lavezzi S. M., de Jong J., Neyens M., Cramer P., DEMİRKAN F., Fraser G., et al.

PHARMACEUTICAL RESEARCH , cilt.36, sa.7, 2019 (SCI-Expanded, Scopus)

47. The Turkish experience with therapeutic plasma exchange: A national survey

Korkmaz S., Medeni S. S., DEMİRKAN F., Besisik S. K., Dadin S. A., ÇAĞLIYAN G. A., et al.

TRANSFUSION AND APHERESIS SCIENCE , cilt.58, sa.3, ss.287-292, 2019 (SCI-Expanded, Scopus)

48. Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma

Fraser G., Cramer P., DEMİRKAN F., Silva R. S., Grosicki S., Pristupa A., et al.

LEUKEMIA , cilt.33, sa.4, ss.969-980, 2019 (SCI-Expanded, Scopus)

49. Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study

Younes A., Brody J., Carpio C., Lopez-Guillermo A., Ben-Yehuda D., Ferhanoglu B., et al.

LANCET HAEMATOLOGY , cilt.6, sa.2, 2019 (SCI-Expanded, Scopus)

50. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial

Moreno C., Greil R., DEMİRKAN F., Tedeschi A., Anz B., Larratt L., et al.

LANCET ONCOLOGY , cilt.20, sa.1, ss.43-56, 2019 (SCI-Expanded, Scopus)

51. Prognostic Factors in Elderly Patients with Diffuse Large B-Cell Lymphoma and Their Treatment Results

ADIYAMAN S. C., ALACACIOĞLU İ., Danyeli A. E., Turkyilmaz D., Sevindik O. G., DEMİRKAN F., et al.

TURKISH JOURNAL OF HEMATOLOGY , cilt.36, sa.2, ss.81-87, 2019 (SCI-Expanded, Scopus, TRDizin)

52. Acute Lymphoblastic Leukemia in Routine Practice: A Turkish Multicenter Study

Ciftciler R., Sevindik O. G., Tekgunduz A. I. E., ERKURT M. A., VURAL F., TURGUT B., et al.

TURKISH JOURNAL OF HEMATOLOGY , cilt.36, sa.3, ss.169-177, 2019 (SCI-Expanded, Scopus, TRDizin)

53. Does Reinfusion of Stem Cell Products on Multiple Days Affect Engraftment?

Medeni S. S., Turkyilmaz D., Acar C., Sevindik O. G., YÜKSEL F., Piskin O., et al.

TURKISH JOURNAL OF HEMATOLOGY , cilt.35, sa.4, ss.271-276, 2018 (SCI-Expanded, Scopus, TRDizin)

54. A Comparison of Fresenius Com.Tec Cell and Spectra Optia Cell Separators for Autologous and Allogeneic Stem Cell Collections: Single Center Experience.

Solmaz S., Kahraman S., Sevindik O. G., Acar C., Turkyilmaz M., ALACACIOĞLU İ., et al.

Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion , cilt.34, sa.4, ss.677-683, 2018 (SCI-Expanded, Scopus)

55. Can Neutrophil-to-Lymphocyte Ratio, Monocyte-to-Lymphocyte Ratio, and Platelet-to-Lymphocyte Ratio at Day+100 be used as a prognostic marker in Multiple Myeloma patients with autologous transplantation?

Medeni S. S., Acar C., Olgun A., Acar A., Seyhanli A., Taskiran E., et al.

CLINICAL TRANSPLANTATION , cilt.32, sa.9, 2018 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

56. Application of apheresis science in Emergency Medicine

DEMİRKAN F., Tekgunduz E.

TRANSFUSION AND APHERESIS SCIENCE , cilt.57, sa.1, ss.1, 2018 (SCI-Expanded, Scopus)

57. A multicenter experience of thrombotic microangiopathies in Turkey: The Turkish Hematology Research and Education Group (ThREG)-TMA01 study

Tekgunduz E., Yılmaz M., Erkurt M. A., Kiki İ., Kaya A. H., Kaynar L., et al.

TRANSFUSION AND APHERESIS SCIENCE , cilt.57, sa.1, ss.27-30, 2018 (SCI-Expanded, Scopus)

58. Brief biography

DEMİRKAN F.

Transfusion and Apheresis Science , cilt.57, sa.1, ss.3, 2018 (SCI-Expanded, Scopus)

59. What is the evidence for the role of therapeutic apheresis in the management of complement-associated thrombotic microangiopathies?

Yildiz S., DEMİRKAN F.

TRANSFUSION AND APHERESIS SCIENCE , cilt.57, sa.1, ss.31-34, 2018 (SCI-Expanded, Scopus)

60. Three-year follow-up of patients with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) receiving ibrutinib plus bendamustine and rituximab (BR) versus placebo plus BR: an update of the HELIOS study

Hallek M., Fraser G., Cramer P., DEMİRKAN F., Silva R. S., Grosicki S., et al.

LEUKEMIA & LYMPHOMA , cilt.58, ss.192-194, 2017 (SCI-Expanded)

61. Current practice of autologous hematopoietic progenitor cell mobilization in adult patients with multiple myeloma and lymphoma: The results of a survey from Turkish hematology research and education group (ThREG)

Tekgunduz E., DEMİRKAN F., VURAL F., GÖKER H., Ozdogu H., KİKİ İ., et al.

TRANSFUSION AND APHERESIS SCIENCE , cilt.56, sa.6, ss.804-808, 2017 (SCI-Expanded, Scopus)

62. Autologous hematopoietic progenitor cell mobilization and collection in adult patients presenting with multiple myeloma and lymphoma: A position-statement from the Turkish Society of Apheresis (TSA)

Tekgunduz E., Arat M., GÖKER H., Ozdogu H., KAYNAR L., Cagirgan S., et al.

TRANSFUSION AND APHERESIS SCIENCE , cilt.56, sa.6, ss.845-849, 2017 (SCI-Expanded, Scopus)

63. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia

Kantarjian H., Stein A., Goekbuget N., Fielding A. K., Schuh A. C., Ribera J., et al.

NEW ENGLAND JOURNAL OF MEDICINE , cilt.376, sa.9, ss.836-847, 2017 (SCI-Expanded, Scopus)

64. Effects of bone marrow fibrosis and angiogenetic structure on autologous hematopoietic stem cell engraftment

Buyukkurt N., ÖZSAN G. H., Ozkal S., SEYDAOĞLU G., ALACACIOĞLU İ., ÖZCAN M. A., et al.

CUKUROVA MEDICAL JOURNAL , cilt.42, sa.3, ss.499-506, 2017 (ESCI, TRDizin)

65. Kronik Myeloid Lösemi Tanılı Hastalarımızın Retrospektif Değerlendirilmesi

KARAMAN A., SOLMAZ Ş., SEVİNDİK Ö. G., ACAR C., KAHRAMAN S., TUNALI S., et al.

DOKUZ EYLÜL TIP FAKÜLTESİ DERGİSİ , cilt.30, sa.3, ss.103-112, 2017 (TRDizin)

66. Tek merkez deneyimi; 156 hematolojik maligniteli hastanın 350 febril nötropeni atağı

KAHRAMAN S., ALP ÇAVUŞ S., TURGUT N., ÖZCAN M. A., YAPAR N., PİŞKİN Ö., et al.

Klinik Tıp Bilimleri Dergisi , cilt.4, sa.6, ss.24-30, 2016 (Hakemli Dergi)

67. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study

Chanan-Khan A., Cramer P., DEMİRKAN F., Fraser G., Silva R. S., Grosicki S., et al.

LANCET ONCOLOGY , cilt.17, sa.2, ss.200-211, 2016 (SCI-Expanded, Scopus)

68. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia

Burger J. A., Tedeschi A., Barr P. M., Robak T., Owen C., Ghia P., et al.

NEW ENGLAND JOURNAL OF MEDICINE , cilt.373, sa.25, ss.2425-2437, 2015 (SCI-Expanded, Scopus)

69. Nilotinib Does Not Alter the Secretory Functions of Carotid Artery Endothelial Cells in a Prothrombotic or Antithrombotic Fashion

Katgi A., Sevindik O. G., Gokbulut A. A., ÖZSAN G. H., YÜKSEL F., Solmaz S. M., et al.

CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS , cilt.21, sa.7, ss.678-683, 2015 (SCI-Expanded, Scopus)

70. Ibrutinib combined with bendamustine/rituximab (BR) in previously treated small lymphocytic lymphoma (SLL): analysis of patients in the HELIOS trial

Chanan-Khan A., Fraser G., Cramer P., DEMİRKAN F., Silva R. S., Pylypenko H., et al.

LEUKEMIA & LYMPHOMA , cilt.56, ss.92-93, 2015 (SCI-Expanded)

71. Ibrutinib combined with bendamustine/rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): subgroup efficacy analyses from the HELIOS trial

Fraser G., Chanan-Khan A., Cramer P., DEMİRKAN F., Silva R. S., Pylypenko H., et al.

LEUKEMIA & LYMPHOMA , cilt.56, ss.98-100, 2015 (SCI-Expanded)

72. Ibrutinib combined with bendamustine/rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): safety analysis in the HELIOS trial

Cramer P., Chanan-Khan A., Fraser G., DEMİRKAN F., Silva R. S., Pylypenko H., et al.

LEUKEMIA & LYMPHOMA , cilt.56, ss.93-94, 2015 (SCI-Expanded)

73. Akut Myeloid Lösemi Hastalarımızın Retrospektif Değerlendirilmesi

SOLMAZ Ş., SEVİNDİK Ö. G., ACAR C., TÜRKYILMAZ D., YİĞİT KAYA S., TUNALI S., et al.

Dokuz Eylül Üniversitesi Tıp Fakültesi Dergisi , cilt.29, sa.2, ss.65-69, 2015 (TRDizin)

74. Renal and Neurological Response with Eculizumab in a Patient with Transplant Associated Thrombotic Microangiopathy after Allogeneic Hematopoietic Progenitor Cell Transplantation

Sevindik O. G., ALACACIOĞLU İ., Katgi A., Solmaz S. M., Acar C., Piskin O., et al.

CASE REPORTS IN HEMATOLOGY , cilt.2015, 2015 (ESCI)

75. Hypoalbuminemia is a surrogate biomarker of poor prognosis in myelodysplastic syndrome even when adjusting for comorbidities

Sevindik O. G., Guc Z., Kahraman S., Solmaz S. M., Katgi A., Acar C., et al.

LEUKEMIA & LYMPHOMA , cilt.56, sa.9, ss.2552-2555, 2015 (SCI-Expanded, Scopus)

76. The Effect of Fc gamma RIIIA Gene Polymorphism on the Treatment of Diffuse Large B-cell Non-Hodgkin Lymphoma: A Multicenter Prospective Observational Study

Buyukkurt N., ÖZCAN M. A., Ergene U., Payzin B., Tunah S., DEMİRKAN F., et al.

TURKISH JOURNAL OF HEMATOLOGY , cilt.32, sa.2, ss.152-157, 2015 (SCI-Expanded, Scopus, TRDizin)

77. IPSET-thrombosis better identifies thrombosis-free survival: A Turkish cohort

Sevindik O. G., Mersin S., Katgi A., TUNALI S., Solmaz S. M., Acar C., et al.

Clinical Lymphoma, Myeloma and Leukemia , cilt.15, sa.6, 2015 (SCI-Expanded, Scopus)

78. Ibrutinib: From Molecule to Medicine

Ayyildiz O., DEMİRKAN F., GÖKER H., HAZNEDAROĞLU İ. C., İLHAN O., Kaynar L. G., et al.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.24, sa.3, ss.4-14, 2014 (SCI-Expanded, Scopus, TRDizin) Sürdürülebilir Kalkınma

79. Is the BFM Regimen Feasible for the Treatment of Adult Acute Lymphoblastic Leukemia? A Retrospective Analysis of the Outcomes of BFM and Hyper-CVAD Chemotherapy in Two Centers

ALACACIOĞLU İ., Medeni S. S., ÖZSAN G. H., Payzin B., Sevindik O. G., Acar C., et al.

CHEMOTHERAPY , cilt.60, sa.4, ss.219-223, 2014 (SCI-Expanded, Scopus)

80. Turkish Chronic Myeloid Leukemia Study: Retrospective Sectional Analysis of CML Patients

ŞAHİN F., SAYDAM G., Comert M., Uz B., Güçlü Y. S., Turan E., et al.

TURKISH JOURNAL OF HEMATOLOGY , cilt.30, sa.4, ss.351-358, 2013 (SCI-Expanded, Scopus, TRDizin)

81. EFFICACY OF POSACONAZOLE PROPYLAXIS IN AML INDUCTION THERAPY, SINGLE CENTER EXPERIENCE

Katgi A., Sevindik O., Solmaz S., Alacacioglu İ., Piskin O., ÖZCAN M. A., et al.

HAEMATOLOGICA , cilt.98, ss.723-724, 2013 (SCI-Expanded, Scopus)

82. Prognostic value of comorbidity indexes in MDS

Guc Z. G., Sevindik O. G., Kahraman S., Alacacioglu İ., Piskin O., Ozsan G. H., et al.

LEUKEMIA RESEARCH , cilt.37, 2013 (SCI-Expanded, Scopus)

83. New paraneoplastic syndrome in chronic basophilic leukemia.

Cehreli C., Ateş H., Cehreli R., Sercan Z., Demirkan F.

International journal of hematology , cilt.97, sa.4, ss.498-504, 2013 (SCI-Expanded, Scopus)

84. Successful hematopoietic engraftment with gray platelets after allogeneic hematopoietic stem cell transplantation from gray platelet syndrome donor

Katgi A., Ataca P., Kahraman S., Sevindik O. G., Sonmez Ü., Solmaz S. M., et al.

BLOOD COAGULATION & FIBRINOLYSIS , cilt.24, sa.2, ss.208-210, 2013 (SCI-Expanded, Scopus)

85. Management of IFI in Febrile Neutropenic Patients: A Case of Invasive Aspergillosis Treated with Liposomal Amphotericin B

Skvindik O. G., Solmaz S. M., Acar C., ALACACIOĞLU İ., Piskin O., ÖZSAN G. H., et al.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.23, sa.3, ss.16-17, 2013 (SCI-Expanded, Scopus, TRDizin) Sürdürülebilir Kalkınma

86. The Management of Invasive Fungal Infections: What to Consider in Empirical Treatment?

DEMİRKAN F., SAYDAM G., ARDA B., ÖZCAN M. A.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.23, sa.3, ss.1-12, 2013 (SCI-Expanded, Scopus, TRDizin)

87. Disseminated Fusarium Infection in an Acute Lymphoblastic Leukemia (ALL) Patient after Allogeneic Bone Marrow Transplantation

Solmaz S. M., Sevindik O. G., Acar C., ALACACIOĞLU İ., Piskin O., ÖZSAN G. H., et al.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.23, sa.3, ss.13-15, 2013 (SCI-Expanded, Scopus, TRDizin) Sürdürülebilir Kalkınma

88. Ischemic stroke after recombinant factor VIIa treatment in acquired hemophilia A patient

Katgi A., Ataca P., Kahraman S., Piskin O., Ozcan M. A., DEMİRKAN F., et al.

BLOOD COAGULATION & FIBRINOLYSIS , cilt.23, sa.1, ss.69-70, 2012 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

89. Occurrence in a case of Philadelphia negative acute lymphoblastic leukemia following treatment for Ewing's sarcoma Ewing sarkom tedavisi sonrası gelişen Philadelphia negatif akut lenfoblastik lösemi olgusu

Katgi A., Kahraman S., Ataca P., Pişkin Ö., ÖZCAN M. A., ÖZSAN G. H., et al.

Marmara Medical Journal , cilt.25, sa.2, ss.100-102, 2012 (Scopus, TRDizin)

90. The Clinical Impact of Low Doses of Dasatinib in Patients with Chronic Myeloid Leukemia

AKSU S., ŞAHİN F., Uz B., Güçlü Y. S., Atay H., KELKİTLİ E., et al.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.22, sa.1, ss.8-14, 2012 (SCI-Expanded, Scopus, TRDizin)

91. The Effect of the Acute Submaximal Exercise on Thrombin Activatable Fibrinolysis Inhibitor Levels in Young Sedentary Males

Kahraman S., BEDİZ C. Ş., Piskin O., AKSU İ., Topcu A., YÜKSEL F., et al.

CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS , cilt.17, sa.4, ss.414-420, 2011 (SCI-Expanded, Scopus)

92. JAK2V617F mutation and thrombosis in the myeloproliferative neoplasms

DEMİRKAN F., Kalkan S., Kahraman S., Tunali S., Katgi A., Piskin O., et al.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS , cilt.9, ss.890, 2011 (SCI-Expanded, Scopus)

93. Current Problems in the Management of Chronic Myeloid Leukemia in Turkey

DEMİRKAN F.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.21, sa.2, ss.24-28, 2011 (SCI-Expanded, Scopus, TRDizin)

94. Serum sickness-like reactions associated with type III insulin allergy responding to plasmapheresis

Bayraktar F., AKINCI B., DEMİRKAN F., Yener S., Yesil S., Kirmaz C., et al.

DIABETIC MEDICINE , cilt.26, sa.6, ss.659-660, 2009 (SCI-Expanded, Scopus)

95. Fatal Disseminated Mucormycosis In A Patient With Mantle Cell non-Hodgkin's Lymphoma: An Autopsy Case

ALACACIOĞLU İ., Kargi A., Ozcan M. A., Piskin O., Solak C., SEÇİL M., et al.

BRAZILIAN JOURNAL OF INFECTIOUS DISEASES , cilt.13, sa.3, ss.238-241, 2009 (SCI-Expanded, Scopus)

96. Prognostic significance of immunohistochemical classification of diffuse large B-cell lymphoma

ALACACIOĞLU İ., ÖZCAN M. A., ÖZKAL S., Piskin O., Turgut N., DEMİRKAN F., et al.

HEMATOLOGY , cilt.14, sa.2, ss.84-89, 2009 (SCI-Expanded, Scopus)

97. Multiple myeloma presenting as massive ascites

Alacacioglu İ., Turgut N., Piskin O., Ozcan M. A., ÖZSAN G. H., DEMİRKAN F., et al.

JOURNAL OF BUON , cilt.14, sa.2, ss.307-308, 2009 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

98. Use of tunnelled catheters in haematological malignancy patients with neutropenia.

Sariosmanoglu N., Ugurlu B., Turgut N. H., DEMİRKAN F., Ozsan H., ERGÖR G., et al.

The Journal of international medical research , cilt.36, sa.5, ss.1103-11, 2008 (SCI-Expanded, Scopus)

99. Diffuse gastrointestinal involvement of mantle cell lymphoma

Meral M., Demirpence M., Goenen C., AKARSU M., Kayahan H., DEMİRKAN F., et al.

TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.19, sa.2, ss.117-120, 2008 (SCI-Expanded, Scopus, TRDizin) Sürdürülebilir Kalkınma

100. Prognostic Factors and Scoring Systems in Chronic Myelomonocytic Leukemia: A Retrospective Analysis of 37 Patients

DEMİRKAN F., ALACACIOĞLU İ., Piskin O., ÖZSAN G. H., ÖZCAN M. A., ÜNDAR B.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.18, sa.4, ss.193-200, 2008 (SCI-Expanded, Scopus, TRDizin) Sürdürülebilir Kalkınma

101. A patient with diffuse large B-cell non-Hodgkin's lymphoma and AA type amyloidosis

Piskin O., Alacacioglu İ., Ozkal S., Ozcan M. A., DEMİRKAN F., ÖZSAN G. H., et al.

JOURNAL OF BUON , cilt.13, sa.1, ss.113-116, 2008 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

102. Myelomatous effusion in plasma-cell leukemia: A case report

ALACACIOĞLU İ., ÖZCAN M., Pişkin Ö., DEMİRKAN F., ÖZSAN G. H., ÜNDAR B.

UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi , cilt.17, sa.3, ss.163-166, 2007 (SCI-Expanded, Scopus, TRDizin)

103. Clinical characteristics and treatment results of primary gastrointestinal lymphoma patients: Single center experience Primer gastrointestinal lenfoma hastalarinin klinik özellikleri ve tedavi sonuçlari: Tek merkez deneyimi

ALACACIOĞLU İ., ÖZCAN M. A., MERAL M., PİŞKİN Ö., DEMİRKAN F., Özsan G. H., et al.

UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi , cilt.17, sa.3, ss.143-150, 2007 (Scopus, TRDizin)

104. Plasma thrombin activatable fibrinolysis inhibitor levels in Behcet's disease

ÖZCAN M. A., Akar S., ALACACIOĞLU İ., Pişkin Ö., YÜKSEL F., Gürler O., et al.

TURKISH JOURNAL OF MEDICAL SCIENCES , cilt.37, sa.5, ss.267-271, 2007 (SCI-Expanded, Scopus, TRDizin)

105. Synergistic effect of imatinib mesylate and fludarabine combination on Philadelphia chromosome-positive chronic myeloid leukemia cell lines

Pişkin Ö., Özcan M., Özsan G. H., Ateş H., Demirkan F., Alacacıoğlu İ., et al.

Turkish Journal of Hematology , cilt.24, sa.1, ss.23-27, 2007 (SCI-Expanded, Scopus, TRDizin)

106. Increased concentration of soluble CD40 ligand in preeclampsia

Alacacioglu İ., Ozcan M. A., Piskin O., Yuksel F., Alacacioglu A., DEMİRKAN F., et al.

CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS , cilt.13, sa.2, ss.201-205, 2007 (SCI-Expanded, Scopus)

107. Elevated thrombin activatable fibrinolysis inhibitor (TAFI) antigen levels in overt and subclinical hypothyroid patients were reduced by levothyroxine replacement

AKINCI B., Comlekci A., Ozcan M. A., Demir T., Yener S., DEMİRKAN F., et al.

ENDOCRINE JOURNAL , cilt.54, sa.1, ss.45-52, 2007 (SCI-Expanded, Scopus)

108. The clinical, haematological and morphological profile of patients with myelodysplastic syndromes: A single institution experience from Turkey

DEMİRKAN F., Alacacioglu İ., Piskin O., Ozsan G. H., AKINCI B., Ozcan M. A., et al.

LEUKEMIA & LYMPHOMA , cilt.48, sa.7, ss.1372-1378, 2007 (SCI-Expanded) Sürdürülebilir Kalkınma

109. Plasma levels of thrombin activatable fibrinolysis inhibitor antigen in active and inactive inflammatory bowel disease

ÖZCAN M. A., AKARSU M., DEMİRKAN F., AKPINAR H., YÜKSEL F., ÖZSAN G. H., et al.

Turkish Journal of Hematology , cilt.23, sa.2, ss.94-99, 2006 (SCI-Expanded, Scopus)

110. The effect of imatinib mesylate on the erythroid colony formation from patients with polycythemia vera in the presence of different cytokines

Pişkin Ö., Özsan G. H., Ateş H., Özcan M. A., Demirkan F., Alacacıoğlu İ., et al.

Turkish Journal of Hematology , cilt.23, sa.3, ss.136-141, 2006 (SCI-Expanded, Scopus)

111. Circulated activated platelets and increased platelet reactivity in patients with Behcet's disease

Akar S., Oezcan M. A., Ateş H., Guerler O., Alacacioglu İ., Oezsan G. H., et al.

CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS , cilt.12, sa.4, ss.451-457, 2006 (SCI-Expanded, Scopus)

112. Akut Lenfoblastik Lösemide İzole Optik Sinir Tutulumu: Olgu Sunumu

ALACACIOĞLU İ., PİŞKİN Ö., BAHÇELİ S., ARIKAN G., ÖZCAN M. A., DEMİRAL A. N., et al.

Dokuz Eylül Üniversitesi Tıp Fakültesi Dergisi , cilt.19, sa.3, ss.181-184, 2005 (TRDizin)

113. Chronic myeloid leukaemia associated with extreme thrombocytosis

ALACACIOĞLU İ., ÖZCAN M. A., Piskin O., DEMİRKAN F., ÖZSAN G. H., ÜNDAR B.

HAEMA , cilt.8, sa.4, ss.701-703, 2005 (Scopus)

114. Bilateral primary orbital non-Hodgkin's lymphoma in a patient with scleroderma: A case report

Alacacioglu İ., Ozcan M. A., Kocak N., Demiral A. N., Piskin O., DEMİRKAN F., et al.

LEUKEMIA & LYMPHOMA , cilt.46, sa.8, ss.1239-1242, 2005 (SCI-Expanded) Sürdürülebilir Kalkınma

115. Cyclo-oxygenase 2 inhibitor, nabumetone, inhibits proliferation in chronic myeloid leukemia cell lines.

Vural F., Ozcan M., Ozsan G. H., Ateş H., Demirkan F., Piskin O., et al.

Leukemia & lymphoma , cilt.46, sa.5, ss.753-6, 2005 (SCI-Expanded, Scopus)

116. Gingival involvement in a patient with CD56⁺ chronic myelomonocytic leukemia

Vural F., Ozcan M. A., Ozsan G. H., Demirkan F., Piskin O., Ateş H., et al.

LEUKEMIA & LYMPHOMA , cilt.45, sa.2, ss.415-418, 2004 (SCI-Expanded) Sürdürülebilir Kalkınma

117. Plasma levels of thrombin activatable fibrinolysis inhibitor in normal and preeclamptic pregnant women.

Alacacioglu İ., Ozcan M., Alacacioglu A., Polat M., Yuksel F., DEMİRKAN F., et al.

Thrombosis research , cilt.114, sa.3, ss.155-9, 2004 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

118. Plasma levels of free tissue factor pathway inhibitor in patients with various thyroid disorders.

Ozcan M., Comlekci A., DEMİRKAN F., Yuksel F., SARI İ., Demir T., et al.

Thrombosis research , cilt.110, sa.4, ss.243-7, 2003 (SCI-Expanded, Scopus)

119. Refractory thrombocytopenia with multilineage dysplasia: A rare type of myelodysplastic syndrome

DEMİRKAN F., ÖZSAN G. H., ÖZCAN M. A., Vural F., ÖZTOP İ., Yüksel E., et al.

Turkish Journal of Haematology , cilt.20, sa.1, ss.25-30, 2003 (SCI-Expanded, Scopus)

120. Spontaneous remission in acute leukemia: A report of two cases

ÖZSAN G. H., DEMİRKAN F., ÖZTOP İ., ÖZCAN M., Vural F., ÜNDAR B.

THOD - Turk Hematoloji-Onkoloji Dergisi , cilt.12, sa.2, ss.99-102, 2002 (Scopus, TRDizin)

121. EBV-associated nasal-type t/natural killer cell lymphoma presenting with polyserositis and rhabdomyolysis

Vural F., DEMİRKAN F., Ozsan G. H., Kargi A., Cabuk M., Ozcan M. A., et al.

LEUKEMIA & LYMPHOMA , cilt.43, sa.9, ss.1859-1863, 2002 (SCI-Expanded) Sürdürülebilir Kalkınma

122. Effect of intraperitoneal administration of low-molecular-weight heparin on plasma tissue factor pathway inhibitor levels in CAPD patients

Demirkan F., Akarsu M., Sifil A., Tutucu K.

NEPHRON , cilt.91, sa.1, ss.162-163, 2002 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

123. Effect of granulocyte-colony-stimulating factor on serum lactate dehydrogenase levels and isoenzymes in a rabbit model

Menekay S., Ozsan G. H., Demirkan F., Ozbek D., Ozcan M. A., Fadiloglu M., et al.

ACTA HAEMATOLOGICA , cilt.107, sa.1, ss.18-22, 2002 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

124. Effect of sialic acid on platelet cryopreservation

Özsan G. H., Pişkin Ö., Demirkan F., Ateş H., Özcan M., Ündar B.

Turkish Journal of Haematology , cilt.18, sa.4, ss.251-257, 2001 (SCI-Expanded, Scopus, TRDizin)

125. Plasma cell leukemia: A report of 5 cases and review of the literature

DEMİRKAN F., ÖZSAN G. H., ÖZCAN M., Vural F., Cabuk M., ÜNDAR B.

Turkish Journal of Haematology , cilt.18, sa.4, ss.275-279, 2001 (SCI-Expanded, Scopus, TRDizin)

126. Increased levels of tissue factor pathway inhibitor may reflect disease activity and play a role in thrombotic tendency in Behçet's disease.

Akarsu M., DEMİRKAN F., Ozsan G. H., Onen F., Yuksel F., Ozkan S., et al.

American journal of hematology , cilt.68, sa.4, ss.225-30, 2001 (SCI-Expanded, Scopus)

127. Hemophagocytic syndrome associated with inappropriate secretion of antidiuretic hormone in lymphoma and acute myeloblastic leukemia: Report of two cases

DEMİRKAN F., Vural F., Ozsan G. H., Ozcan M., Ozkal S., Undar B.

LEUKEMIA & LYMPHOMA , cilt.42, sa.6, ss.1401-1404, 2001 (SCI-Expanded)

128. Concurrent diagnosis of hairy cell leukemia and renal cell carcinoma

Undar B., DEMİRKAN F., Oztop İ., Ozcan M. A., Ozsan G. H.

LEUKEMIA & LYMPHOMA , cilt.42, sa.3, ss.567-568, 2001 (SCI-Expanded) Sürdürülebilir Kalkınma

129. Emergence of Philadelphia positive chronic myeloid leukemia in a patient with Philadelphia negative acute lymphoblastic leukemia

DEMİRKAN F., Oztop İ., Ozsan H., Undar B.

LEUKEMIA & LYMPHOMA , cilt.42, sa.1-2, ss.251-252, 2001 (SCI-Expanded) Sürdürülebilir Kalkınma

130. High lactoferrin levels in disseminated intravascular coagulation and its possible negative role in coagulation.

Ozsan H., Pehlivan M., Demirkan F., Undar B., SAYAN M., Cehreli C.

Thrombosis research , cilt.98, sa.1, ss.111-4, 2000 (SCI-Expanded, Scopus)

131. The use of different prognostic systems applied to myelodysplastic syndromes: A retrospective analysis

DEMİRKAN F., ÇABUK M., ÖZSAN G. H., Pehlivan M., Yuksel E., ÖZTOP İ., et al.

Turkish Journal of Haematology , cilt.17, sa.3, ss.101-109, 2000 (SCI-Expanded, Scopus, TRDizin)

132. The Role of Interleukin-1 Inhibitors on Acute Myeloblastic Leukemia Blast Proliferation; Future Potential for Biotherapy.

Çehreli C., Özsan G. H., Demirkan F., Ateş H., Ündar B., Akyol F., et al.

Turkish journal of haematology : official journal of Turkish Society of Haematology , cilt.16, sa.4, ss.161-6, 1999 (SCI-Expanded, Scopus, TRDizin)

133. Non-Hodgkin Lenfomada Dilde Aktinomikoz

PEHLİVAN M., YENİÇERİOĞLU Y., DEMİRKAN H. M. B., ÖZSAN G. H., DEMİRKAN F., ERDEN E., et al.

FLORA-INFEKSIYON HASTALIKLARI VE KLINIK MIKROBIYOLOJI DERGISI , cilt.3, sa.3, ss.200-203, 1998 (TRDizin)

134. Meme Kanserli Hastalarda CD44, P-Glikoproteini, ve P-53 Metastaz Gelişimini Yansıtabilir mi?

ALAKAVUKLAR M., KOYUNCUOĞLU ÜLGÜN M., CİNGÖZ S., DEMİRKAN H. M. B., CANDA T., ALANYALI H., et al.

Uhod-Uluslararasi Hematoloji-Onkoloji Dergisi , cilt.7, sa.2, ss.73-79, 1997 (SCI-Expanded, Scopus, TRDizin) Sürdürülebilir Kalkınma

135. Meme Kanseri Tedavisinde Adjuvan Kemoterapi Maliyetinin Araştırılması

DEMİRKAN H. M. B., YILMAZ A. U., ALAKAVUKLAR M., ÜNDAR B., DEMİRKAN F., ÖZSAN G. H., et al.

The Journal of Breast Health , cilt.3, sa.4, ss.158-164, 1996 (ESCI)

136. Türkiye'deki Serviks Kanseri Sıklığı Az Gelişmiş Ülkelerle Benzerlik Göstermekte midir?

CEYLAN C., YILMAZ A. U., ÖZSAN G. H., DEMİRKAN H. M. B., ALANYALI H., USLU T., et al.

Acta Oncologica Turcica , cilt.29, sa.1-2, ss.9-13, 1996 (TRDizin) Sürdürülebilir Kalkınma

137. ACUTE EFFECT OF ERYTHROPOIETIN ON CATECHOLAMINE LEVELS IN UREMIA

AKPOLAT T., ARIK N., DEMIRKAN F., BASCI N., OZKAN Y., ISIMER A., et al.

NEPHRON , cilt.64, sa.2, ss.329-330, 1993 (SCI-Expanded, Scopus)

138. EFFECT OF DESMOPRESSIN (DDAVP) ON PROTEIN-C AND PROTEIN-C INHIBITORS IN UREMIA

AKPOLAT T., OZDEMIR O., ARIK N., DEMIRKAN F., SUNGUR C., OZCEBE O., et al.

NEPHRON , cilt.64, sa.2, ss.232-234, 1993 (SCI-Expanded, Scopus)

139. MEDIASTINAL HEMATOMA - A RARE COMPLICATION OF SUBCLAVIAN CATHETERIZATION FOR HEMODIALYSIS

ARIK N., AKPOLAT T., DEMIRKAN F., DEMIRKAZIK F., YASAVUL U., TURGAN C., et al.

NEPHRON , cilt.63, sa.3, ss.354, 1993 (SCI-Expanded, Scopus)

140. SPONTANEOUS PERITONITIS DUE TO BRUCELLA-MELITENSIS IN A PATIENT WITH CIRRHOSIS

DEMIRKAN F., AKALIN H., SIMSEK H., OZYILKAN E., TELATAR H.

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES , cilt.12, sa.1, ss.66-67, 1993 (SCI-Expanded, Scopus)

141. ACUTE EFFECT OF ERYTHROPOIETIN ON PLASMA-RENIN ACTIVITY AND ALDOSTERONE LEVELS IN END-STAGE RENAL-DISEASE

ARIK N., DEMIRKAN F., ERBAS B., ARINSOY T., SUNGUR C., YASAVUL U., et al.

NEPHRON , cilt.60, sa.1, ss.111, 1992 (SCI-Expanded, Scopus)

Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler 85

1. Prospective Real-World Outcomes of Acute Myeloid Leukemia

Karakus V., ILTAR U., Yenihayat E. M., Polat M. G., ÇELİK S., MALKAN Ü. Y., et al.

65th Annual Meeting of the American-Society-of-Hematology (ASH), California, Amerika Birleşik Devletleri, 9 - 12 Aralık 2023, cilt.142, sa.142, (Özet Bildiri)

2. BCR-ABL NEGATİF KRONİK MİYELOPROLİFERATİF NEOPLAZİLERİN KLİNİK, DEMOGRAFİK, MOLEKÜLER VERİLERİNİN RETROSPEKTİF DEĞERLENDİRİLMESİ

Akşit Bozkına Z., Yavuz B., Özsan G. H., Demirkan F., Alacacıoğlu İ.

48. Ulusal Hematoloji Kongresi, Antalya, Türkiye, 2 - 05 Kasım 2022, ss.160-161, (Özet Bildiri) Sürdürülebilir Kalkınma

3. MARJİNAL ZON LENFOMA HASTALARININ KLİNİK VE DEMOGRAFİK VERİLERİNİN RETROSPEKTİF DEĞERLENDİRİLMESİ: TEK MERKEZ DENEYİMİ

Karakaya B., Yavuz B., Karataş A. F., Erdoğan Yücel E., Şeker Ö., Kakcı M., et al.

48. Ulusal Hematoloji Kongresi, Antalya, Türkiye, 2 - 05 Kasım 2022, sa.41, ss.207, (Özet Bildiri) Sürdürülebilir Kalkınma

4. MULTİPL MYELOM’DA UZUN YAŞAM SÜRESİNE SAHİP HASTALARIN KISA YAŞAM SÜRESİNE SAHİP HASTALARLA KIYASLANMASI: TEK MERKEZ DENEYİMİ

Aygün İ. E., Alacacıoğlu İ., Demirkan F., Yavuz B., Karataş A. F., Erdoğan Yücel E., et al.

48. Ulusal Hematoloji Kongresi, Antalya, Türkiye, 2 - 05 Kasım 2022, sa.530, ss.328, (Özet Bildiri) Sürdürülebilir Kalkınma

5. YÜKSEK IGG M PROTEİNİ İLE GELEN MULTİPLE MYELOM OLGUSUNDA BORTEZOMİB TEDAVİSİ SONRASI FLARE SENDROMU

Karataş A. F., Yavuz B., Erdoğan Yücel E., Kakcı M., Şeker Ö., Alacacıoğlu İ., et al.

48. Ulusal Hematoloji Kongresi, Antalya, Türkiye, 2 - 05 Kasım 2022, sa.194, ss.295, (Özet Bildiri)

6. İKİ VAKA NEDENİYLE KRONİK MYELOİD LÖSEMİ VE KRONİK LENFOSİTİK LÖSEMİ BİRLİKTELİĞİ

Erdoğan Yücel E., Karataş A. F., Yavuz B., Kakcı M., Şeker Ö., Alacacıoğlu İ., et al.

48. ULUSAL HEMATOLOJİ KONGRESİ, Antalya, Türkiye, 2 - 05 Kasım 2022, ss.374, (Tam Metin Bildiri) Sürdürülebilir Kalkınma

7. Hafif Zincir Kaçışı: Hafif zincirleri daha sık mı izlemeliyiz?

Yavuz B., Karataş A. F., Erdoğan Yücel E., Alacacıoğlu İ., Demirkan F., Özsan G. H.

19th International Myeloma Society Annual Meeting, California, Amerika Birleşik Devletleri, 25 - 27 Ağustos 2022, sa.166, ss.126, (Tam Metin Bildiri)

8. OTOLOG HEMATOPOETİK KÖK HÜCRE NAKLİ YAPILAN MULTİPLE MYELOM HASTALARINDA ERKEN RELAPS İLE İLİŞKİLİ FAKTÖRLER

Karataş A. F., Yavuz B., Erdoğan Yücel E., Demirkan F., Alacacıoğlu İ., Özcan M. A., et al.

14. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Antalya, Türkiye, 10 - 12 Mart 2022, sa.179, ss.147, (Özet Bildiri)

9. KARACİĞER’DE METASTATİK İKİNCİ PRİMER MALİGNİTEYİ TAKLİT EDEN EKSTRAMEDÜLLER TUTULUM İLE BAŞVURAN MULTİPL MİYELOM VAKASI

Yavuz B., Karataş A. F., Güven S., Altay C., Erdoğan Yücel E., Demirkan F., et al.

14. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Antalya, Türkiye, 10 - 12 Mart 2022, sa.99, ss.162, (Tam Metin Bildiri)

10. SARKOPENİNİN KÖK HÜCRE NAKİL BAŞARISINA ETKİSİ

Erdoğan Yücel E., Alacacıoğlu İ., Karataş A. F., Yavuz B., Kakcı M., Şeker Ö., et al.

14. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Antalya, Türkiye, 10 - 12 Mart 2022, sa.44, ss.104-105, (Özet Bildiri)

11. İKİ VAKA NEDENİ İLE ALLOJENEİK KÖK HÜCRE NAKLİNDE GEÇ SİTOPENİ

Yavuz B., Erdoğan Yücel E., Karataş A. F., Güven S., Demirkan F., Alacacıoğlu İ., et al.

14. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, 10 - 12 Mart 2022, sa.125, ss.120, (Tam Metin Bildiri)

12. MYELODİSPLASTİK HASTALIK İLE TAKİP SONRASI HODGKİN LENFOMA :BİR OLGU SUNUMU

Delibalta D., Karataş A. F., Yavuz B., Erdoğan Yücel E., Güven S., Demirkan F., et al.

47.Ulusal Hematoloji Kongresi, Antalya, Türkiye, 4 - 07 Kasım 2021, sa.411, ss.305, (Özet Bildiri)

13. İLERİ YAŞ HODGKİN LENFOMA HASTALARININ ÖZELLİKLERİ VE TEDAVİ SONUÇLARININ RETROSPEKTİF ANALİZİ: TEK MERKEZ DENEYİMİ

Erdoğan Yücel E., Karataş A. F., Yavuz B., Güven S., Özsan G. H., Alacacıoğlu İ., et al.

47.Ulusal Hematoloji Kongresi, Antalya, Türkiye, 4 - 07 Kasım 2021, sa.385, ss.208-209, (Özet Bildiri) Sürdürülebilir Kalkınma

14. APLASTİK ANEMİ TEDAVİSİ SONRASI ANAPLASTİK T HÜCRELİ LENFOMA: BİR OLGU SUNUMU

Karataş A. F., Yavuz B., Erdoğan Yücel E., Güven S., Özsan G. H., Demirkan F., et al.

47.Ulusal Hematoloji Kongresi, Antalya, Türkiye, 4 - 07 Kasım 2021, sa.388, ss.316, (Tam Metin Bildiri)

15. Relaps/Refrakter Marjinal Zon Lenfoma'da İbrutinib Tedavisi: Tek Merkez Deneyimi

Karakaya B., Yavuz B., Karataş A. F., Erdoğan Yücel E., Güven S., Alacacıoğlu İ., et al.

47. Ulusal Hematoloji Kongresi, Antalya, Türkiye, 4 - 07 Kasım 2021, ss.214-215, (Özet Bildiri)

16. MULTİPL MYELOMDA HAFİF ZİNCİR KAÇIŞI: AGRESİF PROGRESYONUN ERKEN BİR İPUCU MU?

Yavuz B., Karataş A. F., Erdoğan Yücel E., Güven S., Alacacıoğlu İ., Demirkan F., et al.

8. International Congress on Leukemia Lymphoma Myeloma, 21 - 22 Mayıs 2021, sa.40, ss.57-58, (Özet Bildiri)

17. MULTİPL MYELOM TEDAVİSİNDE PACE-BENZERİ REJİMLER

Karataş A. F., Yavuz B., Özcan M. A., Erdoğan Yücel E., Güven S., Demirkan F., et al.

8. International Congress on Leukemia Lymphoma Myeloma, 21 - 22 Mayıs 2021, sa.74, ss.50-51, (Tam Metin Bildiri)

18. RELAPS REFRAKTER ALK NEGATİF ANAPLASTİK BÜYÜK HÜCRELİ LENFOMA: BİR OLGU SUNUMU

Karataş A. F., Yavuz B., Erdoğan Yücel E., Güven S., Alacacıoğlu İ., Demirkan F., et al.

13. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, 2 - 03 Nisan 2021, sa.140, ss.161, (Tam Metin Bildiri)

19. HEMATOPOETİK KÖK HÜCRE NAKİLLERİNDE HİPOKALEMİ: BİR ENGRAFTMAN BELİRTECİ OLABİLİR Mİ?

Karataş A. F., Yavuz B., Erdoğan Yücel E., Güven S., Alacacıoğlu İ., Demirkan F., et al.

13. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, 2 - 03 Nisan 2021, sa.128, ss.131-132, (Özet Bildiri)

20. COVID-19 PANDEMİ DÖNEMİNDE HEMATOPOİETİK KÖK HÜCRE TRANSPLANTASYONU: TEK MERKEZ DENEYİMİ

Güven S., Alacacıoğlu İ., Yavuz B., Erdoğan Yücel E., Karataş A. F., Demirkan F., et al.

13. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, 2 - 03 Nisan 2021, sa.139, ss.135, (Özet Bildiri)

21. KONKOMİTAN KRONİK MİYELOMONOSİTİK LÖSEMİ VE EKSTRANODAL DİFFÜZ BÜYÜK B HÜCRELİ LENFOMA: OLGU SUNUMU

Erdoğan Yücel E., Yavuz B., Karataş A. F., Güven S., Demirkan F., Özsan G. H., et al.

46. Ulusal Hematoloji Kongresi, 28 - 31 Ekim 2020, sa.242, ss.182, (Özet Bildiri)

22. OLGULARLA HİPEREOZİNOFİLİK SENDROM YÖNETİMİ: TEK MERKEZ DENEYİMİ

Karataş A. F., Yavuz B., Erdoğan Yücel E., Can G., Güven S., Demirkan F., et al.

46. Ulusal Hematoloji Kongresi, 28 - 31 Ekim 2020, sa.284, ss.198-199, (Özet Bildiri)

23. İKİ OLGU NEDENİ İLE MULTİPLE MYELOMADA SERBEST HAFİF ZİNCİR KAÇIŞI VE SERBEST HAFİF ZİNCİR TAKİBİNİN ÖNEMİ

Yavuz B., Karataş A. F., Güven S., Erdoğan Yücel E., Alacacıoğlu İ., Demirkan F., et al.

46. ULUSAL HEMATOLOJİ KONGRESİ, 28 - 31 Ekim 2020, sa.287, ss.132-133, (Özet Bildiri)

24. RELAPS/REFRAKTER SANTRAL SİNİR SİSTEMİ LENFOMASINDA İBRUTİNİB MONOTERAPİSİ: İKİ OLGU SUNUMU

Yavuz B., Şeyhanlı A., Demirkan F., Güven S., Erdoğan Yücel E., Karataş A. F., et al.

46. Ulusal Hematoloji Kongresi, 28 - 31 Ekim 2020, sa.235, ss.195-196, (Özet Bildiri)

25. BLİNATUMOMAB İLİŞKİLİ SİTOKİN FIRTINASI: STEROİD İLE YÖNETİM

Yavuz B., Karataş A. F., Erdoğan Yücel E., Güven S., Demirkan F., Alacacıoğlu İ., et al.

46. ULUSAL HEMATOLOJİ KONGRESİ, 28 - 31 Ekim 2020, sa.288, ss.199, (Özet Bildiri) Sürdürülebilir Kalkınma

26. Karaciğerde metastatik hastalık benzeri tutulum gösteren Multiple Myelom

Güven S., Yavuz B., Alacacıoğlu İ., Şeyhanlı A., Erdoğan Yücel E., Karataş A. F., et al.

46. Ulusal Hematoloji Kongresi, 28 - 31 Ekim 2020, sa.274, ss.194-195, (Özet Bildiri)

27. Neutropenia analysis of venetoclax monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia: Pooled data from VENICE-I and -II Phase IIIb trials.

Anderson M. A., Davids M. S., Kater A. P., Cochrane T., Demirkan F., Herishanu Y., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 - 31 Mayıs 2020, cilt.38, (Özet Bildiri)

28. Turkish Acute Lymphoblastic Leukemia Registry, Retrospective Phase Data

Demirkan F., Ciftciler R., Sevindik O. G., Tekgunduz E., ERKURT M. A., VURAL F., et al.

61st Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Florida, Amerika Birleşik Devletleri, 7 - 10 Aralık 2019, cilt.134, (Özet Bildiri)

29. THE EFFECT OF SARCOPENIA ON PROGNOSIS IN PATIENTSWITH DIFFUSEL LARGE B-CELL LYMPHOMA

SOLMAZ Ş., ÖZGÜL H. A., SEYHANLI A., ALTAY C., ALACACIOĞLU İ., SEÇİL M., et al.

7th International Congress on Leukemia Lymphoma Myeloma, Türkiye, 2 - 04 Mayıs 2019, (Özet Bildiri)

30. RETROSPECTIVE EVALUATION OF IMMUNOMUDULATORYAGENTS RESPONSE AND SIDE EFFECTS IN RELAPSEDREFRACTOY MYELOMA PATIENTS: REAL LIFE EXPERIENCE

erdoğan ç., SEYHANLI a., ALACACIOĞLU İ., PİŞKİN Ö., DEMİRKAN F., ÖZCAN M. A., et al.

7th International Congress on Leukemia Lymphoma Myeloma, 2 - 04 Mayıs 2019, cilt.36, (Tam Metin Bildiri)

31. THE CORRELATION BETWEEN INTERIM IMAGING RESULTSAND DISEASE PROGNOSIS OF PATİENTS WİTH HODGKINAND DIFFUSE LARGE B CELL LYMPHOMA: SINGLE CENTEREXPERIENCE

erdoğan ç., SEYHANLI a., ALACACIOĞLU İ., PİŞKİN Ö., DEMİRKAN F., ÖZCAN M. A., et al.

7th International Congress on Leukemia Lymphoma Myeloma, 2 - 04 Mayıs 2019, cilt.36, (Tam Metin Bildiri)

32. TİGESİKLİNE BAĞLI GELİŞEN İMMUN TROMBOSİTOPENİ OLGUSU

ÖNTAN M. S., OLGUN A., ŞEYHANLI A., ALACACIOĞLU İ., PİŞKİN Ö., ÖZCAN M. A., et al.

45. Ulusal Hematoloji Kongresi, Antalya, Türkiye, 1 - 03 Mart 2019, (Özet Bildiri)

33. ALLOJENİK KEMİK İLİĞİ NAKLİ YAPILAN OLGULARIMIZDACMV ANTİJENEMİ VE CMV-DNA PCR SONUÇLARININKARŞILAŞTIRILMASI

KESKİNKILIÇ M., SOLMAZ Ş., SEYHANLI A., APPAK Ö., SAYINER A. A., PİŞKİN Ö., et al.

11. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Türkiye, 1 - 02 Mart 2019, (Özet Bildiri)

34. NÜKS MULTİPLE MYELOMA’DA ETKİN BİR TEDAVİ OLANİKİNCİ OTOLOG KÖK HÜCRE NAKLİ: TEK MERKEZ DENEYİMİ

SEYHANLI A., ÇETİN D., ALACACIOĞLU İ., DEMİRKAN F., SOLMAZ Ş., ÖZCAN M. A., et al.

11. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Türkiye, 1 - 02 Mart 2019, (Özet Bildiri)

35. Ibrutinib plus Obinutuzumab Versus Chlorambucil plus Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results from Phase 3 iLLUMINATE

Moreno C., Greil R., DEMİRKAN F., Tedeschi A., Anz B., Larratt L., et al.

60th Annual Meeting of the American-Society-of-Hematology (ASH), California, Amerika Birleşik Devletleri, 1 - 04 Aralık 2018, cilt.132, (Özet Bildiri)

36. ULUSAL, ÇOK MERKEZLİ GRUP UYGUNSUZ ’0’ GRUP KULLANIMININ RETROSPEKTİF DEĞERLENDİRİLMESİ

TORET E., TÜFEKÇİ Ö., KÜÇÜKASLAN A. Ş., EKER İ., ANDIÇ N., ÖZER T. B., et al.

44. ulusal hematoloji kongresi, Antalya, Türkiye, 31 Ekim - 04 Kasım 2018, (Özet Bildiri)

37. Ulusal, Çok Merkezli Grup Uygunsuz ‘0’ Grup Kullanımının Retrospektif Değerlendirilmesi

TÖRET E., TÜFEKÇİ Ö., Küçükarslan A. Ş., EKER İ., ANDIÇ N., Özer Belgemen T., et al.

44. Ulusal Hematoloji Kongresi, 31 Ekim - 04 Kasım 2018, (Tam Metin Bildiri)

38. Granulocytic sarcoma with unusual localizations (breast and stomach) without bone marrow involvement after allogeneic transplantation

Solmaz S., Seyhanli A., Alacacioglu İ., DEMİRKAN F., Ozsan G., Ozkal S., et al.

9th International Eurasian Hematology Oncology Congress (EHOC), İstanbul, Türkiye, 17 - 20 Ekim 2018, cilt.73, (Özet Bildiri)

39. ALLOGENİK KÖK HÜCRE NAKLİ SONRASI CMVMONİTORİZASYONUNDA PP65 VE PCR SONUÇLARININKARŞILAŞTIRILMASI

KESKİNKILIÇ M., SOLMAZ Ş., SEYHANLI A., ACAR A., OLGUN A., TASKIRAN E., et al.

10. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler KongresiBildiri Özetleri, Türkiye, 1 - 03 Mart 2018, (Özet Bildiri)

40. OTOLOG NAKİL YAPILAN MULTİPL MYELOMHASTALARIMIZIN YANIT DURUMLARI VE SONUÇLARIETKİLEYEN FAKTÖRLER

SOLMAZ Ş., OLGUN A., ACAR A., SEYHANLI A., TASKIRAN E., PİŞKİN Ö., et al.

10. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Türkiye, 1 - 03 Mart 2018, (Özet Bildiri)

41. MULTİPL MYELOM OTOLOG NAKİL 100.GÜN NÖTROFİLLENFOSİT VE PLATELET LENFOSİT ORANININ SAĞKALIMAETKİSİ

SOLMAZ Ş., OLGUN A., ACAR A., SEYHANLI A., TASKIRAN E., ACAR C., et al.

10. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Türkiye, 1 - 03 Mart 2018, (Özet Bildiri)

42. OTOLOG NAKİL YAPILAN MULTİPL MYELOMHASTALARINDA REİNFÜZYON GÜN SAYISININENGRAFMANA VE HASTANEDE KALIŞ SÜRESİNE ETKİSİ

SOLMAZ Ş., TÜRKYILMAZ D., ACAR C., SEVİNDİK Ö. G., YİĞİT KAYA S., ACAR A., et al.

10. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Türkiye, 1 - 03 Mart 2018, (Özet Bildiri)

43. Effect of Different Treatment Patterns to Cost Effectiveness in Chronic Lymphocytic Leukemia Patients, Turkish CLL Study Group

DEMİRKAN F., Vural F., Tekinalp A., Sevindik O. G., Sayinalp N., Kaynar L., et al.

59th Annual Meeting of the American-Society-of-Hematology (ASH), Georgia, Amerika Birleşik Devletleri, 9 - 12 Aralık 2017, cilt.130, (Özet Bildiri)

44. İZMİR İLİ HASTANE KAN MERKEZLERİNİN YAPISAL VE FONKSİYONEL DURUMU: ÇOK MERKEZLİ ANKET ÇALIŞMASI

YILMAZ A. F., DEĞİRMENCİ DÖŞKAYA A., DEMİRKAN F., UZUN B., KÖSE Ş., KARACA B., et al.

43. Ulusal Hematoloji Kongresi, Türkiye, 1 - 04 Kasım 2017, (Özet Bildiri)

45. DEKOMPANSE KARACİĞER YETMEZLİĞİ İLE PREZANTEOLAN ANAPLASTİK BÜYÜK HÜCRELİ LENFOMA, OLGUSU

YİĞİT KAYA S., ACAR A., OLGUN A., SOLMAZ Ş., TÜRKYILMAZ D., SEYHANLI A., et al.

43. ULUSAL HEMATOLOJİ KONGRESİ, Türkiye, 1 - 04 Kasım 2017, (Özet Bildiri)

46. THE NEW PROGNOSTIC SIGNIFICANCE OFPLATELET-TO-LYMPHOCYTE RATIOS IN PATIENTSWITH MULTIPLE MYELOMA

SOLMAZ Ş., UZUN Ö., ACAR C., SEVİNDİK Ö. G., ALACACIOĞLU İ., PİŞKİN Ö., et al.

6th International Congress on Leukemia Lymphoma Myeloma, 11 - 13 Mayıs 2017, (Özet Bildiri)

47. CHRONIC GRAFT VERSUS HOST DISEASE MANIFESTING AS POLYMYOSITIS AND HYPERCALCEMIA - AN UNCOMMON PRESENTATION

Şeyhanlı A., TÜRKYILMAZ D., KAYA S., OLGUN A., GARİP ACAR A., ŞİRİN D., et al.

6. INTERNATIONAL CONGRESS OF LEUKEMIA LYMPHOMA MYELOMA, Antalya, Türkiye, 11 - 13 Mayıs 2017, (Tam Metin Bildiri)

48. GRANULOCYTIC SARCOMA MANIFESTING WITH ATYPICAL LOCALIZATION

TÜRKYILMAZ D., ÖZKAL S., acar a. g., kaya s. Y., Şeyhanlı A., PİŞKİN Ö., et al.

6. International congress of leukemia lymphoma myeloma, Antalya, Türkiye, 11 - 13 Mayıs 2017, (Tam Metin Bildiri)

49. GRANULOCYTIC SARCOMA MANIFASTING WITH ATYPICAL LOCALIZATION: 3 CASE REPORTS

TÜRKYILMAZ D., ÖZKAL S., GARİP A., YİĞİT KAYA S., ŞEYHANLI A., PİŞKİN Ö., et al.

6. INTERNATIONAL CONGRESS OF LUEKEMIA LYMPHOMA MYELOMA, Antalya, Türkiye, 11 - 13 Mayıs 2017, (Özet Bildiri)

50. CHRONIC GRAFT VERSUS HOST DISEASE MANIFASTING AS POLYMYOSITIS AND HYPERCALCEMIA: AN UNCOMMON PRESANTATION

ŞEYHANLI A., TÜRKYILMAZ D., YİĞİT KAYA S., OLGUN A., GARİP A., ŞİRİN D., et al.

6. INTERNATIONAL CONGRES OF LEUKEMIA LYMPHOMA MYELOMA, Antalya, Türkiye, 11 - 13 Mayıs 2017, (Özet Bildiri)

51. Systemic Exposure of Rituximab Increased By Ibrutinib: Pharmacokinetic Results from the Helios Trial

Cramer P., DEMİRKAN F., Fraser G., Pristupa A., Bartlett N. L., Dilhuydy M., et al.

58th Annual Meeting and Exposition of the American-Society-of-Hematology, California, Amerika Birleşik Devletleri, 3 - 06 Aralık 2016, cilt.128, (Özet Bildiri)

52. 11q Deletion (del11q) Is Not a Prognostic Factor for Adverse Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Ibrutinib: Pooled Data from 3 Randomized Phase 3 Studies

Kipps T. J., Hillmen P., DEMİRKAN F., Grosicki S., Coutre S. E., Barrientos J. C., et al.

58th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), California, Amerika Birleşik Devletleri, 3 - 06 Aralık 2016, cilt.128, (Özet Bildiri)

53. A Multicenter Experience of Thrombotic Microangiopathies in Turkey: The Turkish Hematology Research and Education Group (ThREG)-TMA01 Study

Tekgunduz E., YILMAZ M., ERKURT M. A., KİKİ İ., Kaya A. H., KAYNAR L., et al.

58th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), California, Amerika Birleşik Devletleri, 3 - 06 Aralık 2016, cilt.128, (Özet Bildiri)

54. Is It Time for Early Cessation of Empirical Antibiotherapy in Patients Presenting with Febrile Neutropenia? Preliminary Results of a Risk-Adapted Approach in a Hematology Clinic

Kaya A. H., Tekgunduz E., Bekdemir F., Batgi H., Yigenoglu T., Ulu B. U., et al.

58th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), California, Amerika Birleşik Devletleri, 3 - 06 Aralık 2016, cilt.128, (Özet Bildiri)

55. SİSPLATİN İNFÜZYONU SONRASI GELİŞEN ASEMPTOMATİK BRADİKARDİ OLGUSU

GARİP A., Olgun A., C. A., TÜRKYILMAZ D., YİĞİT KAYA S., ŞEYHANLI A., et al.

42. Ulusal Hematoloji Kongresi, Antalya, Türkiye, 19 - 22 Ekim 2016, (Özet Bildiri)

56. BLINATUMOMAB IMPROVED OVERALL SURVIVAL IN PATIENTS WITH RELAPSED OR REFRACTORY PHILADELPHIA NEGATIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA IN A RANDOMIZED, OPEN-LABEL PHASE 3 STUDY (TOWER)

Topp M. S., Stein A., Goekbuget N., Fielding A., Schuh A., Ribera Santasusana J. M., et al.

21st Congress of the European-Hematology-Association, Copenhagen, Danimarka, 9 - 12 Haziran 2016, cilt.101, ss.24-25, (Özet Bildiri)

57. IBRUTINIB PLUS BENDAMUSTINE AND RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): 2-YEAR FOLLOW-UP INCLUDING MRD FROM THE HELIOS STUDY

Fraser G., Cramer P., DEMİRKAN F., Santucci Silva R., Grosicki S., Janssens A., et al.

21st Congress of the European-Hematology-Association, Copenhagen, Danimarka, 9 - 12 Haziran 2016, cilt.101, ss.150-151, (Özet Bildiri)

58. Ibrutinib (I) plus bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): a 2-year follow-up of the HELIOS study.

Fraser G., Cramer P., DEMİRKAN F., Silva R. S., Pylypenko H., Grosicki S., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 3 - 07 Haziran 2016, cilt.34, (Özet Bildiri)

59. The effect of stem cell viability and storage time

Medeni S. S., Ozsan G., Acar C., Sevindik O., Turkyilmaz D., DEMİRKAN F., et al.

42nd Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, Valencia, İspanya, 3 - 06 Nisan 2016, cilt.51, (Özet Bildiri)

60. Insights into the Management of Adverse Events in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Experience from the Phase 3 HELIOS Study of Ibrutinib Combined with Bendamustine/Rituximab

Chanan-Khan A., Cramer P., DEMİRKAN F., Fraser G., Silva R. S., Pylypenko H., et al.

57th Annual Meeting of the American-Society-of-Hematology, Florida, Amerika Birleşik Devletleri, 5 - 08 Aralık 2015, cilt.126, (Özet Bildiri)

61. Improvement of Quality of Response with Ibrutinib Plus Bendamustine/Rituximab Vs Placebo Plus Bendamustine/Rituximab for Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Cramer P., Chanan-Khan A., Fraser G., DEMİRKAN F., Silva R. S., Pylypenko H., et al.

57th Annual Meeting of the American-Society-of-Hematology, Florida, Amerika Birleşik Devletleri, 5 - 08 Aralık 2015, cilt.126, (Özet Bildiri)

62. Quality of Life in Multiple Myeloma Validation of the Turkish Version of the Qlq My20 Instrument

SEVİNDİK Ö. G., ALACACIOĞLU İ., Payzın K. B., YAVUZŞEN T., Özdemirkıran F. G., YILDIRIM T., et al.

15. th International Myeloma Workshop, Roma, İtalya, 23 - 26 Eylül 2015, ss.202

63. IPSET THROMBOSIS BETTER IDENTIFIES THROMBOSIS FREE SURVIVAL

SEVİNDİK Ö. G., MERSİN S., katgı a., tunalı s., solmaz ş., ACAR C., et al.

EHA CONGRESS, 11 - 13 Haziran 2015, cilt.100, ss.537-538, (Özet Bildiri)

64. IBRUTINIB COMBINED WITH BENDAMUSTINE/RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): FIRST RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY

Cramer P., Chanan-Khan A., DEMİRKAN F., Fraser G., Santucci Silva R., Pylypenko H., et al.

20th Congress of the European-Hematology-Association, Vienna, Avusturya, 11 - 14 Haziran 2015, cilt.100, ss.55-56, (Özet Bildiri)

65. IS BERLIN-FRANKFURT-MUNSTER (BFM) REGIMEN FEASIBLE FOR TREATMENT OF ADULT ACUTE LYMPHOBLASTIC LEUKEMIA: RETROSPECTIVE ANALYSIS OF OUTCOME OF ADULT ALL TREATED WITH BFM AND HPER-CVAD PROTOCOLS

Alacacioglu İ., Solmaz S., Ozsan H., PAyzin B., Sevindik G., Acar C., et al.

20th Congress of European-Hematology-Association, Vienna, Avusturya, 11 - 14 Haziran 2015, cilt.100, ss.637-638, (Özet Bildiri)

66. Ibrutinib combined with bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): First results from a randomized, double-blind, placebo-controlled, phase III study

Chanan-Khan A. A. A., Cramer P., DEMİRKAN F., Fraser G., Silva R. S., Pylypenko H., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2015, cilt.33, (Özet Bildiri)

67. IPSET-THROMBOSIS BETTER IDENTIFIES THROMBOSIS FREE SURVIVAL

Sevindik O. G., Mersin S., Katgi A., Tunali S., Solmaz S. M., Acar C., et al.

20th Congress of European-Hematology-Association, Vienna, Avusturya, 11 - 14 Haziran 2015, cilt.100, ss.537, (Özet Bildiri)

68. POST-AUTHORIZATION SAFETY OF LENALIDOMIDE plus DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: EARLY SAFETY REPORT OF TURKISH PASS STUDY

Tuglular A. T. F., Pehlivan M., Sari H. I., Ayyildiz M. O., SAYDAM G., SÖNMEZ M., et al.

20th Congress of European-Hematology-Association, Vienna, Avusturya, 11 - 14 Haziran 2015, cilt.100, ss.734, (Özet Bildiri)

69. Comparing the efficacy of generic Imatinib formulations with the original Imatinib as the frontline tyrosine kinase inhibitor in chronic phase chronic myeloid leukemia

DEMİRKAN F., SEVİNDİK Ö. G., KARAMAN A., ALACACIOĞLU İ., Solmaz S. M., ÖZSAN G. H.

51st Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2015, cilt.33, (Özet Bildiri)

70. HYPOALBUMINEMIA IS A SURROGATE BIOMARKER OF POORPROGNOSIS IN MYELODYSPLASTIC SYNDROME EVEN WHENADJUSTED WITH COMORBIDITIES

SEVİNDİK Ö. G., Güç Z., KAHRAMAN S., Medini Ş., Katgı A., ACAR C., et al.

13th International Symposium on Myelodyspastic Syndromes /, 29 Nisan - 02 Mayıs 2015, cilt.39, ss.123, (Özet Bildiri)

71. HYPOALBUMINEMIA IS A SURROGATE BIOMARKER OF POOR PROGNOSIS IN MYELODYSPLASTIC SYNDROME EVEN WHEN ADJUSTED WITH COMORBIDITIES

Sevindik O., Guc Z., KAHRAMAN S., Medeni S., Katgi A., Acar C., et al.

13th International Symposium on Myelodysplastic Syndromes (MDS), Washington, Kiribati, 29 Nisan - 02 Mayıs 2015, cilt.39, (Özet Bildiri)

72. Situations affecting hematopoietic stem cell apheresis

Medeni S. S., DEMİRKAN F., Sevindik G., Turkyilmaz D., Kaya S. Y., Acar C., et al.

41st Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, İstanbul, Türkiye, 22 - 25 Mart 2015, cilt.50, (Özet Bildiri)

73. Does reinfusion of stem cell products in multiple days affect engraftment?

Alacacioglu İ., Turkyilmaz D., Medeni S. S., Acar C., Sevindik O. G., Piskin O., et al.

41st Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, İstanbul, Türkiye, 22 - 25 Mart 2015, cilt.50, (Özet Bildiri)

74. Maximum storage time that affect the viability of stem cells

Medeni S. S., Acar C., Yigitkaya S., Turkyilmaz D., Sevindik G., Alacacioglu İ., et al.

41st Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, İstanbul, Türkiye, 22 - 25 Mart 2015, cilt.50, ss.5556, (Özet Bildiri)